DMIIR
Drugs Made In America Acquisition II Corp. RightNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
—
52W High
$0.17
52W Low
$0.06
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Drugs Made In America Acquisition II Corp. Right
Drugs Made In America Acquisition II Corp. Right (DMIIR) is a special purpose acquisition company (SPAC) focused on mergers with innovative firms in the pharmaceutical sector, emphasizing the enhancement of domestic drug manufacturing capabilities. With a seasoned management team at the helm, DMIIR is poised to capitalize on the increasing demand for affordable and accessible medications produced in the U.S. By pursuing strategic acquisitions, DMIIR aims to deliver significant shareholder value while strengthening the critical healthcare infrastructure necessary for a more resilient American healthcare system.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | -812,113 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -0.32% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.28 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $50.26M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
158.85%
HV 20-Day
145.53%
HV 30-Day
133.15%
HV 60-Day
119.92%
HV Rank
—
Volatility is currently expanding
Data last updated: 7/9/2026